Recognition by the Swiss Biotech Association for SOPHiA GENETICS' Outstanding Contributions as a Leader in Data-Driven Medicine SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the
(0)
-
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive form of Non-Hodgkin s Lymphoma (NHL), representing 30-40% of cases. Nearly half of DLBCL patients are not cured by first-line treatment, leaving a large number of patients at risk of worsening disease
1
-
Naratuximab emtansine, the most advanced CD37 targeting antibody drug conjugate (ADC) in clinical development for DLBCL, showed promising safety and efficacy results in combination with rituximab for the treatment of R/R DLBCL and other B-cell malignancies
-
Phase II data presented by Dr. Moshe Yair Levy at the 2021 European Hematology Association (EHA) conference as a late breaking abstract (LB1903) demonstrated that the naratuximab emtansine/rituximab combination could represent a new treatment approach, particularly for heavily pre-treated
Share this article
-
Pre-clinical in vitro research from the Mondor Institute of Biomedical Research (INSERM U955) has shown evidence for the effectiveness of alisporivir against the replication of
SARS-COV-2 (COVID-19)
-
A randomized, investigator-initiated, phase II study, conducted by the AP-HP (Greater Paris University Hospitals), has been launched to assess the efficacy and safety of the compound in 90 hospitalized COVID-19 patients from multiple centers in France
-
Debiopharm has opted to forgo any financial benefit from treatment and pledges to donate all proceeds to a non-profit foundation dedicated to infectious disease research
LAUSANNE, Switzerland, Jan. 18, 2021 /PRNewswire/
Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company,